News | July 30, 2024
GSK and Flagship partner to discover novel medicines and vaccines
GSK and Flagship to jointly fund up to $150 million upfront
GSK and Flagship to jointly fund up to $150 million upfront
Lupin can receive a potential total consideration of up to USD 84 million based on future contingent milestones
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
_256_384.jpg)
Cipla had earlier invested € 15 million in Ethris in 2022
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Subscribe To Our Newsletter & Stay Updated
